DelveInsight’s, “Myelodysplastic Syndrome Pipeline Insight 2024” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
- DelveInsight’s Myelodysplastic Syndrome pipeline report depicts a robust space with 120+ active players working to develop 150+ pipeline therapies for Myelodysplastic Syndrome treatment.
- The leading Myelodysplastic Syndrome Companies working in the market include Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.
- Promising Myelodysplastic Syndrome Therapies in the various stages of development include Deferasirox, Bortezomib, Decitabine and cedazuridine, Luspatercept, Epoetin Alfa, and others.
- May 2024:- Bristol-Myers Squibb- The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
- May 2024-Washington University School of Medicine- This phase I trial studies the side effects and the best dose of vosaroxin when given together with azacitidine in treating patients with myelodysplastic syndromes. Drugs used in chemotherapy, such as vosaroxin and azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Request a sample and discover the recent advances in Myelodysplastic Syndrome treatment drugs @ Myelodysplastic Syndrome Pipeline Outlook Report
Myelodysplastic Syndrome Overview
Myelodysplastic syndrome (MDS) is a heterogeneous group of hematologic neoplasms classically described as a clonal disorder of hematopoietic stem cells leading to dysplasia and ineffective hematopoiesis in the bone marrow. Some patients with MDS may have a transformation into acute myeloid leukemia (AML). MDS is usually diagnosed in older patients over the age of 65. Clinical manifestations include a decrease in the number of red blood cells (RBC), platelets, and white blood cells (WBC). The disease course is variable.
The mainstay of treatment for MDS involves assessment of symptoms and potential morbidity attributed to the disease. Patients do not always require treatment as long as they are asymptomatic and most can be treated with supportive measures such as intermittent blood or platelet transfusions. MDS often portends an indolent or gradual course, though some patients have risk factors that put them at risk for transformation into AML.
Myelodysplastic Syndrome Emerging Drugs Profile
- MBG453: Novartis
- Tamibarotene: Syros Pharmaceuticals
- CA-4948: Curis
- RVU120: Ryvu Therapeutics
Find out more about Myelodysplastic Syndrome treatment drugs @ Drugs for Myelodysplastic Syndrome Treatment
Myelodysplastic Syndrome Therapeutics Assessment
There are approx. 120+ key Myelodysplastic Syndrome companies which are developing the therapies for Myelodysplastic Syndrome. The Myelodysplastic Syndrome companies which have their Myelodysplastic Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Novartis.
DelveInsight’s Myelodysplastic Syndrome report covers around 150+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Learn more about the emerging Myelodysplastic Syndrome pipeline therapies @ Myelodysplastic Syndrome Clinical Trials
Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Myelodysplastic Syndrome Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Myelodysplastic Syndrome Companies
Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.
Dive deep into rich insights for new drugs for Myelodysplastic Syndrome Treatment, visit @ Myelodysplastic Syndrome Drugs
Scope of the Myelodysplastic Syndrome Pipeline Report
- Coverage- Global
- Myelodysplastic Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Myelodysplastic Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Myelodysplastic Syndrome Companies- Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.
- Myelodysplastic Syndrome Therapies- Deferasirox, Bortezomib, Decitabine and cedazuridine, Luspatercept, Epoetin Alfa, and others.
For further information on the Myelodysplastic Syndrome Pipeline Therapeutics, reach out @ Myelodysplastic Syndrome Treatment Drugs
Table of Content
- Introduction
- Executive Summary
- Myelodysplastic Syndrome: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Myelodysplastic Syndrome– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- MBG453: Novartis
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- CA-4948: Curis
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- RVU120: Ryvu Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Myelodysplastic Syndrome Key Companies
- Myelodysplastic Syndrome Key Products
- Myelodysplastic Syndrome- Unmet Needs
- Myelodysplastic Syndrome- Market Drivers and Barriers
- Myelodysplastic Syndrome- Future Perspectives and Conclusion
- Myelodysplastic Syndrome Analyst Views
- Myelodysplastic Syndrome Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/